Eli Lilly Agrees to Buy Calytrix Bio in Deal Worth Up to $1.5 Billion for Rare Blood Disorder Treatment

Eli Lilly acquisition of Calytrix Bio: Eli Lilly Acquisition of Calytrix Bio: Eli Lilly has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash. The deal expands Lilly's work on rare blood disorders, centred on a preclinical antibody targeting mutant calreticulin, though the upfront payment and completion date have not been disclosed.

Eli Lilly Acquisition of Calytrix Bio, Digi Mart USA News: Eli Lilly and Co has agreed to acquire privately held biotechnology company Calytrix Bio for up to $1.5 billion in cash, according to a publisher report. The deal is structured as a definitive agreement under which Calytrix shareholders will receive an upfront payment followed by additional payments tied to clinical and regulatory milestones.

The companies have not disclosed the size of the initial payment or an expected completion date for the transaction. Eli Lilly shares were up more than 1% at $1,466.58 in New York trading on Monday morning, the report said.

The acquisition centres on Calytrix’s lead experimental programme, a preclinical antibody designed to treat essential thrombocythemia and myelofibrosis driven by mutations in the calreticulin protein. Both conditions belong to a group of diseases called myeloproliferative neoplasms, in which the bone marrow produces excessive numbers of abnormal blood cells.

The antibody is designed to target both Type 1 and Type 2 mutant calreticulin, with the aim of eliminating disease-driving cells while preserving healthy tissue and blood-cell production. Calytrix said existing drug treatments for these conditions mainly manage symptoms and complications, which it sees as an opportunity for therapies that act on the underlying mutations and could potentially alter the course of the diseases.

The programme remains at the preclinical stage and must undergo clinical development before its safety and effectiveness in patients can be established. Calytrix chief executive Brad Prosek said the company was founded to develop treatments that could do more than manage symptoms and welcomed Lilly’s plans to advance the programme through clinical trials.

The acquisition broadens Lilly’s presence in the myeloproliferative neoplasm field and builds on its existing blood cancer portfolio, which includes the approved treatment Jaypirca. Calytrix was founded in 2025 by JP Morgan Life Sciences Private Capital and later received backing from Westlake BioPartners and Avoro Ventures.

Felix Reeves

Felix Reeves is an experienced digital journalist and news writer dedicated to delivering informative, engaging, and reader-focused content across a wide range of topics. With a strong interest in journalism, media, and digital publishing, he covers stories that matter to readers across the United States and around the world.

His coverage extends across multiple categories, including breaking news, world affairs, politics, business, finance, technology, health, lifestyle, entertainment, education, science, sports, travel, automotive developments, and trending stories.

Felix is passionate about researching important developments, understanding emerging trends, and transforming complex information into clear, accessible, and engaging articles.

### Areas of Coverage

- Breaking News & Latest Updates
- US News & International News
- Politics & Government
- Business & Finance
- Technology & Artificial Intelligence
- Health & Wellness
- Lifestyle & Fashion
- Entertainment & Celebrity News
- Education & Career
- Science & Environment
- Sports & Trending Stories
- Travel & Tourism
- Automotive & Transportation
- Personal Finance & Consumer News
- Digital Trends & General Interest

### Journalism & Editorial Approach

Felix believes that quality journalism should inform, educate, and empower readers. His approach emphasizes thorough research, factual accuracy, balanced reporting, and easy-to-understand storytelling.

He aims to cover a diverse range of subjects while maintaining editorial quality, credibility, and relevance in every article.

### Professional Mission

Through his contributions to Digi Mart, Felix Reeves strives to keep readers informed about the latest developments, important stories, and emerging trends from different parts of the world.

His goal is simple: Deliver reliable information, meaningful insights, and stories that matter.

Stay Informed. Stay Connected. Stay Ahead.

Leave a Reply

Your email address will not be published. Required fields are marked *

Sports

Explore Digimart Global